- BioAtla (BCAB, Financial) presents promising initial data for BA3182 at the ESMO 2025 Congress.
- The Phase 1 trial shows tumor size reduction in heavily pretreated metastatic adenocarcinoma patients.
- Reassuring safety profile with low-grade and manageable adverse events noted.
BioAtla, Inc. (BCAB) has announced encouraging data from the Phase 1 trial of BA3182, their dual-conditionally binding EpCAM x CD3 bispecific T-cell engager, at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress. The study involved 39 patients with heavily pretreated metastatic adenocarcinoma, receiving doses between 0.0026 mg and 0.6 mg weekly.
Key findings revealed that five patients experienced objective tumor size reductions ranging from -8% to -25%. Notably, two patients with colorectal carcinoma demonstrated prolonged progression-free intervals of 11 and 14 months. The adverse events reported were predominantly low-grade and manageable, with subcutaneous administration showing a superior plasma profile compared to intravenous dosing.
BioAtla continues the dose escalation process, now administering 1.2 mg weekly. Updated data from the Phase 1 trial is anticipated in the second half of 2025, potentially broadening therapeutic options for over one million patients worldwide with various types of adenocarcinomas, including colorectal, breast, and pancreatic cancers.
